Berthelot W, Sirois C, Julien A, Amiable N, Bessette L, Desaulniers P
Rheumatol Int. 2025; 45(3):44.
PMID: 39921727
DOI: 10.1007/s00296-025-05804-8.
Nomura M, Sugihara T, Baba H, Hosoya T, Kamiya M, Ishizaki T
Arthritis Res Ther. 2025; 27(1):22.
PMID: 39901281
PMC: 11789366.
DOI: 10.1186/s13075-025-03491-1.
Hong B, You S, Kim J, Kim M, Lee N, Lee K
Front Immunol. 2025; 15:1439082.
PMID: 39877346
PMC: 11772891.
DOI: 10.3389/fimmu.2024.1439082.
Takanashi S, Kaneko Y
J Clin Med. 2025; 13(24).
PMID: 39768516
PMC: 11679914.
DOI: 10.3390/jcm13247594.
DOnofrio B, De Stefano L, Bozzalla Cassione E, Morandi V, Cuzzocrea F, Sakellariou G
Arthritis Res Ther. 2024; 26(1):192.
PMID: 39516929
PMC: 11545058.
DOI: 10.1186/s13075-024-03431-5.
Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?.
Hofman Z, Roodenrijs N, Nikiphorou E, Kent A, Nagy G, Welsing P
Rheumatology (Oxford). 2024; 64(1):65-73.
PMID: 39383505
PMC: 11701314.
DOI: 10.1093/rheumatology/keae544.
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients.
Cincinelli G, Maioli G, Posio C, Favalli E, Ingegnoli F, Caporali R
Arthritis Res Ther. 2024; 26(1):161.
PMID: 39289770
PMC: 11406730.
DOI: 10.1186/s13075-024-03390-x.
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat.
Ekin A, Misirci S, Gorunen A, Coskun B, Yagiz B, Dalkilic E
Med Princ Pract. 2024; 34(1):75-86.
PMID: 39288740
PMC: 11805541.
DOI: 10.1159/000541488.
Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.
Qi W, Robert A, Singbo N, Ratelle L, Fortin P, Bessette L
Adv Rheumatol. 2024; 64(1):55.
PMID: 39107865
DOI: 10.1186/s42358-024-00396-6.
Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
Novella-Navarro M, Ruiz-Esquide V, Lopez-Juanes N, Chacur C, Monjo-Henry I, Nuno L
Clin Rheumatol. 2024; 43(9):2817-2823.
PMID: 39009920
DOI: 10.1007/s10067-024-07070-8.
A Preliminary Survey of Rheumatologists on the Management of Late-onset Rheumatoid Arthritis in Japan.
Takanashi S, Kaneko Y, Kawahito Y, Kida T, Sugihara T, Kojima T
Intern Med. 2024; 63(24):3299-3306.
PMID: 38692915
PMC: 11729168.
DOI: 10.2169/internalmedicine.3288-23.
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
Caron B, Habert A, Bonsack O, Camara H, Jeanbert E, Parigi T
United European Gastroenterol J. 2024; 12(5):605-613.
PMID: 38594841
PMC: 11176900.
DOI: 10.1002/ueg2.12547.
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab.
Tsumoto K, Takeuchi T
BioDrugs. 2024; 38(3):341-351.
PMID: 38584236
PMC: 11055793.
DOI: 10.1007/s40259-024-00648-3.
Effectiveness and safety of treat-to-target strategy for methotrexate-naïve rheumatoid arthritis patients >75 years of age.
Matsumoto T, Sugihara T, Hosoya T, Ishizaki T, Kubo K, Kamiya M
Rheumatol Adv Pract. 2024; 8(1):rkae019.
PMID: 38425693
PMC: 10904149.
DOI: 10.1093/rap/rkae019.
Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding.
Yu Z, Gao L, Zang Y, Cheng L, Gao W, Xu Y
Immun Inflamm Dis. 2024; 12(2):e1166.
PMID: 38415932
PMC: 10832310.
DOI: 10.1002/iid3.1166.
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.
Bertsias A, Flouri I, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S
RMD Open. 2024; 10(1).
PMID: 38242549
PMC: 10806522.
DOI: 10.1136/rmdopen-2023-003808.
Comorbidities and chance of remission in patients with early rheumatoid arthritis receiving methotrexate as first-line therapy: a Swedish observational nationwide study.
Tidblad L, Westerlind H, Delcoigne B, Askling J, Saevarsdottir S
RMD Open. 2023; 9(4).
PMID: 38123483
DOI: 10.1136/rmdopen-2023-003714.
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment.
Novella-Navarro M, Cabrera-Alarcon J, Lopez-Juanes N, Villalba A, Fernandez Fernandez E, Monjo I
RMD Open. 2023; 9(3).
PMID: 37775112
PMC: 10546133.
DOI: 10.1136/rmdopen-2023-003382.
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
Jung J, Lee E, Kim J, Suh C, Shin K, Kim J
Arthritis Res Ther. 2023; 25(1):174.
PMID: 37726808
PMC: 10507947.
DOI: 10.1186/s13075-023-03165-w.
Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
Garcia-Salinas R, Sanchez-Prado E, Mareco J, Ronald P, Ruta S, Gomez R
Rheumatol Int. 2023; 43(10):1821-1828.
PMID: 37269430
DOI: 10.1007/s00296-023-05349-8.